Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the new orally active iron chelator, ICL670, is
as safe as deferoxamine in preventing accumulation of iron in the body while a patient is
undergoing repeated blood transfusions.